spacer
home > epc > spring 2009 > non-clinical acceleration
PUBLICATIONS
European Pharmaceutical Contractor

Non-Clinical Acceleration

In the course of the development of a new drug, the selection of the most promising molecule from a series of closely related molecules for further development is timeconsuming and expensive. Data provided by pharmacodynamic studies conducted in vitro or in vivo, or by pharmacological studies in test animals, are often inadequate to differentiate with sufficient reliability those molecules which should be excluded from further development. When considering start-up and smaller companies in particular, it is extremely important to focus as early as possible on the most promising candidate for further development, in order to save time, resources and costs.

In such a case, it must be emphasised that the most reliable information about a drug can really only be generated using human subjects (volunteers or patients). The results obtained when going first time in man are therefore of pivotal relevance, and enable a sponsor to get a much more accurate picture of the pharmacological potential of a molecule.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Ruediger Haecker is a qualified physician, specialising in biochemistry. He completed his academic education in Leipzig and Magdeburg, and has held academic positions as a Lecturer and Full Professor of Biochemistry in Dresden and Leipzig, Germany. Since 1990, Ruediger has held several positions researching the developments of human and veterinary pharmaceuticals. He has worked on around 30 scientific publications and written more than 150 papers and presentations. Ruediger joined Harlan Laboratories Ltd in 2001, working as a Scientific Advisor in non-clinical development, specialising in international drug regulatory affairs.

Steve Dean has a background in genetics and cell biology, and holds a PhD in oncology from the Paterson Laboratories in Manchester, UK. Following postdoctoral work both in the US and the UK, he began his industrial career as a Genetic Toxicologist at Covance, holding positions as Head of Genetic Toxicology and managing Toxicology Operations in Harrogate. In 1999 he took the opportunity to work in Italy as Managing Director of RTC in Rome, then returned in 2002 to the UK as Group Sales Director for HLS in Cambridgshire. In recent years he has continued to participate in scientific activities, is a past President of the UK Environmental Mutagen Society and a Eurotox-registered toxicologist. He recently relocated to Switzerland as Director of Business Development for Harlan Laboratories CRS Division.

spacer
Ruediger Haecker
spacer
spacer
spacer
Steve Dean
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices

Phillips-Medisize

An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed clinical trials can all benefit from these novel, next-generation technologies.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement